<DOC>
	<DOC>NCT02600169</DOC>
	<brief_summary>This study is a retrospective cohort study. A database will be created from the data available of all patients that have participate in the named patient program for pembrolizumab in the Netherlands. This database will be used for analysis of response markers and for an evaluation of adverse events.</brief_summary>
	<brief_title>Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab</brief_title>
	<detailed_description>This study is a retrospective cohort study. A database will be created from the data available of all patients that have participate in the named patient program for pembrolizumab in the Netherlands. This database will be used for analysis of response markers and for an evaluation of adverse events.</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>All patients that were eligible for treatment with pembrolizumab in the Named Patient Program in the Netherlands.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>